Abstract

Three boron compounds which have been considered for use in the treatment of glioma patients, by neutron capture irradiation, have been evaluated in terminal individuals. They are 3-amino-4-carboxybenzeneboronic acid, m-boronosuccinanilic acid, and sodium perhydrodecaborate. The latter compound has been shown to be the most promising from the standpoint of low toxicity and has, in fact, been isolated unchanged, from the urine. Low toxicity is seen to be correlated with biological inertness and high chemical stability.